Who is the CEO of Roquefort Therapeutics plc?

The CEO of Roquefort Therapeutics plc is Stephen Paul West CA.

What industry does Roquefort Therapeutics plc belong to?

Roquefort Therapeutics plc operates in the Biotechnology industry within the Healthcare sector.

Where is Roquefort Therapeutics plc headquartered?

Roquefort Therapeutics plc is headquartered at Eccleston Yards, London, SW1W 9NF, GB.

What is the IPO date of Roquefort Therapeutics plc?

Roquefort Therapeutics plc went public on March 22, 2021.

How many employees does Roquefort Therapeutics plc have?

Roquefort Therapeutics plc has approximately 7 full-time employees.

Roquefort Therapeutics plc

ROQ.L•LSE

Healthcare

Biotechnology

£1.65

£0.00(0.00%)

Roquefort Therapeutics plc (ROQ.L) Company Profile & Overview

Explore Roquefort Therapeutics plc’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.

Roquefort Therapeutics plc (ROQ.L) Company Profile & Overview

Roquefort Therapeutics plc operates as a biotechnology research company. The company engages in the research and development of drugs targeting Midkine, a circulating growth factor protein and pro-inflammatory mediator for the treatment of cancer. Roquefort Therapeutics plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

SectorHealthcare

IndustryBiotechnology

CEOStephen Paul West CA

Contact Information

https://www.roquefortinvest.com

44 20 3290 9339

Eccleston Yards, London, SW1W 9NF

Company Facts

7 Employees

IPO DateMar 22, 2021

CountryGB

Actively Trading

Frequently Asked Questions

;